Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100892 · ClinicalTrials.gov registry record · Phase 3
Cystic Fibrosis - Insulin Deficiency, Early Action
A Phase 3 study of Diabetes and Cystic Fibrosis, sponsored by Sydney Children's Hospitals Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 6
- Study locations
NCT01100892 is a Phase 3 study of Diabetes and Cystic Fibrosis that has completed, run by Sydney Children's Hospitals Network. The registered enrollment target is 100 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT01100892, a Phase 3 study of Diabetes and Cystic Fibrosis, has completed, sponsored by Sydney Children's Hospitals Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 6
- Study locations
Study Summary
Cystic Fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.
Conditions Studied
Interventions
- DRUG Once-daily insulin detemir
Study Locations (6)
New South Wales
- John Hunter Children's Hospital - New Lambton
- Sydney Children's Hospital - Randwick
- Children's Hospital at Westmead - Westmead
Colorado
- Children's Hospital Colorado - Denver
Queensland
- Lady Cilento Children's Hospital - Brisbane
South Australia
- Women's and Children's Hospital - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-12 |
| Est. Completion | 2023-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100892
The ClinicalTrials.gov registry entry for NCT01100892 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Sydney Children's Hospitals Network, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Once-daily insulin detemir is the first listed.
NCT01100892 reports 6 study locations spanning 4 distinct geographic areas - top geographies include New South Wales, Colorado, Queensland.
Frequently Asked Questions
What is clinical trial NCT01100892 about?
NCT01100892 is a clinical study titled "Cystic Fibrosis - Insulin Deficiency, Early Action". Cystic Fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine wh...
What is the current status of trial NCT01100892?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2010-12. Estimated completion is 2023-02.
What conditions does trial NCT01100892 study?
This clinical trial studies the following conditions: Diabetes, Cystic Fibrosis.
What interventions are being tested in trial NCT01100892?
The interventions under investigation include: Once-daily insulin detemir (DRUG).
Who is sponsoring clinical trial NCT01100892?
This trial is sponsored by Sydney Children's Hospitals Network, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01100892 being conducted?
This trial has 6 study locations across Colorado, New South Wales, Queensland, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial to Assess Chelation Therapy in Critical Limb Ischemia
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
COMPLETED · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.